Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
VYNE Therapeutics Inc. (VYNE) had Return on Tangible Equity of -31.41% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$0.42M |
|
$-28.45M |
|
-- |
|
$0.42M |
|
$29.68M |
|
$-29.26M |
|
$1.39M |
|
$-27.87M |
|
$-27.87M |
|
$-27.87M |
|
$-27.87M |
|
$-28.45M |
|
$-27.87M |
|
$-29.26M |
|
$-29.51M |
|
10.27M |
|
10.27M |
|
$-2.78 |
|
$-2.78 |
|
| Balance Sheet Financials | |
$95.96M |
|
-- |
|
$1.72M |
|
$97.69M |
|
$7.54M |
|
-- |
|
$1.41M |
|
$8.95M |
|
$88.73M |
|
$88.73M |
|
$88.73M |
|
14.10M |
|
| Cash Flow Statement Financials | |
$-25.34M |
|
$-57.35M |
|
$82.39M |
|
$30.98M |
|
$30.67M |
|
$-0.30M |
|
$3.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-6900.47% |
|
-6900.47% |
|
-6960.61% |
|
-6573.59% |
|
-6710.38% |
|
$-25.34M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-31.41% |
|
|
Return on Tangible Equity |
-31.41% |
-28.53% |
|
-31.41% |
|
$6.29 |
|
$-2.47 |
|
$-2.47 |
|